Description: The pharma stock yields more than 4x the S&P 500 average.

Description: Earlier this week, Bristol Myers Squibb announced that the European Commission approved its CAR-T cell therapy Breyanzi for adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic treatments, including a Bruton’s tyrosine kinase inhibitor. This expanded approval, based on positive trial data, further establishes Breyanzi as a key asset in the company’s oncology portfolio, opening up access for eligible patients across the EU and EEA countries. We’ll now...

Description: Wondering if Bristol-Myers Squibb is a bargain or overpriced? Let’s dig into what’s behind the numbers so you can decide with confidence. After a rocky start to the year, Bristol-Myers Squibb has staged an impressive rebound, gaining 15.6% in the last month and 6.5% in just the past week. However, it is still down 13.3% year-to-date. Investor sentiment has been shaped by headlines ranging from major drug approvals to strategic partnerships, which have fueled recent optimism about...

Description: GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.

Description: Bristol-Myers has lagged behind the broader S&P 500 Index, and Wall Street remains cautious about this stock.

Description: Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.

Description: We came across a bullish thesis on Bristol-Myers Squibb Company on CompoundingLab’s Substack. In this article, we will summarize the bulls’ thesis on BMY. Bristol-Myers Squibb Company’s share was trading at $49 recently. BMY’s trailing and forward P/E were 16.6 and 8 respectively according to Yahoo Finance. Bristol-Myers Squibb Co. (NYSE: BMY) appears modestly undervalued following its recent […]

Description: The global follicular lymphoma market is witnessing growth due to advancements in targeted therapies and immunotherapies. Follicular lymphoma, an indolent form of non-Hodgkin lymphoma, often presents challenges like relapse and treatment resistance, underscoring the need for novel treatment strategies. Innovative therapies such as monoclonal antibodies and CAR T-cell therapies are enhancing patient outcomes by providing more precise and less toxic options compared to traditional chemotherapy. Ke

Description: Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.

Description: PRINCETON, N.J., November 26, 2025--Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference

Description: The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,

Description: Bristol-Myers Squibb (BMY) shares have seen mixed movement over the past month, with the stock rebounding nearly 9% but still trading below this year’s highs. Investors continue to monitor the company’s performance trends and financials. See our latest analysis for Bristol-Myers Squibb. Even after this month’s strong 8.9% share price return, Bristol-Myers Squibb is still trying to regain its footing following a tough year for total shareholders, who are down nearly 15%. While short-term...

Description: Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.

Description: The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.

Description: PRINCETON, N.J., November 24, 2025--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

Description: Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.

Description: A number of stocks jumped in the afternoon session after a Politico report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. The proposal would extend subsidies set to expire at the end of the year, with new eligibility limits for individuals with incomes up to 700% of the federal poverty line. These subsidies, a key part of the Affordable Care Act (ACA), help lower the cost of health insurance for consumers, making them crucial for insurers focused on the

Description: The industry is showing enthusiasm for novel technologies that improve safety and carry innovation potential including in vivo CAR-Ts.

Description: PRINCETON, N.J., November 24, 2025--Bristol Myers Squibb to Host Hematology-Focused Investor Event

Description: Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Description: Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.

Description: The medical technology stock is in a consolidation pattern and testing a key level. The biotech had a beat-and-raise quarter.

Description: Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.

Description: BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.

Description: For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date. It’s a challenge that Bristol Myers Squibb is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022. Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.

Description: These six top blue-chip dividend stocks remain outstanding ideas for investors seeking to move away from tech stocks.

Description: Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Value Equity Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. The US equity market continued the rally in the third quarter, with the S&P 500 returning 8.1% and the Russell 1000 Value surging 5.3%. […]

Description: Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.

Description: Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: MONTREAL, November 19, 2025--Ability Biotherapeutics, a next-generation biotherapeutics company developing logic-gated antibodies for safer and more effective immunotherapies, announces the appointment of Dr. John Burke and Dr. Alan Korman to its Scientific Advisory Board.

Description: PRINCETON, N.J., November 18, 2025--Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers

Description: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease marked by gradual scarring, limiting lung function. The exact cause is unknown, but it combines genetic and environmental factors. With symptoms like shortness of breath and fatigue, IPF lacks a cure, necessitating effective treatments. Increasing cases, driven by aging populations and better diagnosis, spur R&D on new therapies. Companies like Hoffmann-La Roche and Bristol-Myers Squibb innovate with targeted and biologic therapie

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.

Description: PRINCETON, N.J., November 18, 2025--Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers

Description: BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.

Description: December S&P 500 E-Mini futures (ESZ25) are up +0.02%, and December Nasdaq 100 E-Mini futures (NQZ25) are up +0.09% this morning, pointing to a muted open on Wall Street as cautious sentiment prevailed at the start of a busy week.

Description: Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Best Passive Income Stocks to Buy Right Now. On November 13, Scotiabank bega‍n cove‌rage o⁠f Bristol-Myers Squibb Company (NYSE:BMY) with a Sect⁠or Perform rat‍ing and s⁠et a price targ‍et of $4‌5, as reported by The Fly. ‍In the third quart⁠er of 2025, Bristol-Myers Squibb Company (NYSE:BMY) […]

Description: A delivery company got a boost from a new partnership announcement on Friday, Nov. 14, 2025, while the termination of a clinical trial weighed on a pharmaceutical firm.

Description: Shares of Bristol Myers Squibb slumped Friday after the company scrapped a study testing a treatment for acute coronary syndrome.

Description: Health care stocks fell late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Hea

Description: US equity indexes were mixed ahead of Friday's close amid selective dip-buying in technology and inf

Description: US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec

Description: Bristol said it had decided to stop one of its ongoing Phase 3 trials testing an experimental blood thinner called milvexian.

Description: Major U.S. equities indexes were mixed Friday afternoon, following a sharp decline Thursday fueled by a selloff of tech stocks.

Description: US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Virgin Galactic (SPCE) shares rising while missing third quarter revenue estimates and narrowing its net losses below forecasts, Applied Materials (AMAT) forecasting a drop in chip equipment sales, and Bristol Myers Squibb (BMY) halting its trial for a blood clot drug. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Health care stocks were declining premarket Friday, with the Health Care Select Sector SPDR Fund (XL

Description: Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Description: PRINCETON, N.J., November 14, 2025--Update on Phase 3 Librexia ACS Trial

Description: Bristol Myers Squibb completed a €5 billion senior unsecured note offering and announced an expanded collaboration with Sarah Cannon Research Institute to accelerate development and access to innovative cancer therapies by streamlining clinical trial delivery across more than 200 U.S. locations. This combination of large-scale financing and partnership expansion positions the company to enhance its oncology pipeline while improving financial flexibility for future initiatives. We'll explore...

Description: NVIDIA, Micron Technology and Thermo Fisher lead today's top analyst picks, each showing strong growth trends and strategic advances.

Description: Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.

Description: Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.

Description: Turn health into wealth with these three high-yielding dividend stocks.

Description: Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index gaining 1.6% and th

Description: Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the Health Care Sel

Description: Precision medicine and next-gen biologics are transforming patient care. Despite cost-related challenges, key players like AbbVie, Johnson & Johnson, and Bristol-Myers Squibb are leading innovations.Dublin, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The "Psoriatic Arthritis Market - A Global and Regional Analysis: Focus on Drug Type and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. The growing prevalence of autoimmune diseases, particularly among individu

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: Curious about whether Bristol-Myers Squibb is undervalued or could be a hidden gem? You're not alone, as plenty of investors are asking whether this giant is offering opportunity or risk at today's price. After a long dip early this year, the stock has rebounded, gaining 6.9% in the last week and 10.8% over the past month. However, it remains down 14.2% year to date. Recent headlines have centered on strategic acquisitions in the biotech space and ongoing regulatory developments. Both have...

Description: NASHVILLE, Tenn., November 12, 2025--Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, and Bristol Myers Squibb (NYSE: BMY), a leading biopharmaceutical company, today announced an expanded strategic collaboration aimed at accelerating the development of innovative cancer therapies and increasing access to clinical trials for patients across the U.S.

Description: The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively trad

Description: The Winn Awards community welcomes 79 new physician-researchers from 23 states NORTHAMPTON, MA / ACCESS Newswire / November 12, 2025 /Originally published by The Robert A. Winn Excellence in Clinical Trials Award Program The Robert A. Winn Excellence ...

Description: Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations FDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec HAMBURG, DE / ACCESS Newswire / November ...

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the best undervalued stocks to buy under $50. Bristol-Myers Squibb Company (NYSE:BMY) was assigned a Hold rating by Bernstein analyst Courtney Breen on November 3, who maintained the price target at $58. Bristol-Myers Squibb Company (NYSE:BMY) announced strong Q3 results on October 30, with both revenue and EPS […]

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer offered insights on. Answering a caller’s query about the stock, Cramer stated: “I’m backing off on it because I gotta tell you, I’m trying to see some good news in this Cobenfy that I was really all in on and I’m not getting that […]

Description: EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.

Description: Bristol-Myers Squibb (BMY) grabbed investor attention after releasing its third-quarter results, which showed a sharp rise in net income and higher revenue guidance for 2025. The company highlighted strength across its growth portfolio. See our latest analysis for Bristol-Myers Squibb. Bristol-Myers Squibb has seen its share price rebound recently, with a 7.5% return over the past month following upbeat quarterly results and an outlook upgrade. However, the 1-year total shareholder return...

Description: With significant upside potential and hedge fund interest, Beam Therapeutics Inc. (NASDAQ:BEAM) secured a spot on our list of the 15 stocks set to explode in 2026. On November 5, 2025, Clear Street increased its price target on Beam Therapeutics Inc. (NASDAQ:BEAM) from $34 to $37, while maintaining a “Buy” rating. The revised target reflected […]

Description: Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer recently shared thoughts on. Cramer showed his disappointment in the company’s schizophrenia medicine sales, as he commented: “Look, I, my Charitable Trust owns Bristol, looks like a mistake because I, I believed in Cobenfy, which is a, a pretty good product, but it’s not […]

Description: Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.

Description: Evotec SE reported its third-quarter 2025 results, showing quarterly sales of €163.89 million and a net loss of €43.09 million, alongside news that it received a US$25 million payment from Bristol Myers Squibb for progress within their neuroscience collaboration. While sales declined year-over-year in the quarter, Evotec’s ongoing partnership achievements underscore the company’s ambitions in innovative drug discovery for neurodegenerative diseases. We'll examine how milestone payments for...

Description: DUBLIN, November 06, 2025--Prothena today reported financial results for the third quarter and first nine months of 2025 and provided business highlights.

Description: Contingent value rights have become common in biotechnology deals. More than half of all transactions this year include them, according to a Jefferies report in October.

Description: The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. Co

Description: With the Federal Reserve likely to continue lowering rates until next summer, now is the time to load the boat on five of our favorite blue-chip dividend giants.

Description: Bristol-Myers Squibb Company's ( NYSE:BMY ) strong earnings report was rewarded with a positive stock price move. Our...

Description: JACKSONVILLE, Fla., November 05, 2025--Redwire Corporation (NYSE:RDW, "Redwire" or the "Company"), a global leader in space and defense technology solutions, today announced results for its third quarter ended September 30, 2025.

Description: PRINCETON, N.J., November 05, 2025--Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes

Description: Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Description: The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of similar treatments for hypertrophic cardiomyopathy.

Description: PHILADELPHIA & SAN FRANCISCO, November 04, 2025--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with Bristol Myers Squibb ("BMS") to support the development of Dispatch’s DISP-10 program. Under the agreement, BMS will provide idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T therapy, for use in Dispatch’s first U.S. Phase 1 trial, expected to in

Description: PRINCETON, N.J., November 03, 2025--Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions

Description: Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging anti-tumor activity and manageable safety profile of pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L11 and VEGF-A, in first disclosed interim data from global Phase 2 trial in extensive-stage small cell lung cancer Plan to initiate additional pivotal t

Description: Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and

Description: PRINCETON, N.J., November 03, 2025--Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes

Description: Bristol-Myers Squibb Company ( NYSE:BMY ) just released its third-quarter report and things are looking bullish...

Description: Bristol-Myers Squibb (BMY) is facing a 6% annual revenue decline projected over the next three years. The company has turned profitable in the past five years, growing earnings by 10.8% per year. Earnings are expected to rise by a moderate 4.6% annually moving forward, although this pace lags the broader US market. Recent results were clouded by a one-off $6.6 billion loss that affected reported earnings quality for the twelve months to September 2025. See our full analysis for Bristol-Myers...

Description: The Craneware Group convened leaders from 25 major U.S. health systems, alongside representatives from Beacon/ESP (Berkeley Research Group) and Apexus, the HRSA 340B Prime Vendor, at its U.S. headquarters this week to align on readiness for the now-approved 340B Rebate Model Pilot Program.

Description: Bristol-Myers Squibb's (BMY) lack of update on its ADEPT-2 phase-3 Alzheimer's psychosis trial or th

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the best NYSE stocks to buy and hold for the next decade. On October 27, Bristol Myers Squibb announced new Week 52 data from its pivotal Phase 3 POETYK PsA-1 trial. These results further confirmed the efficacy and safety of Sotyktu (deucravacitinib) for treating adults with active psoriatic […]

Description: The AF market offers opportunities driven by new pipeline drugs such as FXI/FXIa inhibitors addressing bleeding concerns and growing prevalence of treated AF cases. However, growth is challenged by generic erosion of NOACs and competition from cost-effective generics, hindering new entry uptake.Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation: Eight-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering.The table below pres

Description: In October 2025, Bristol-Myers Squibb reported positive Phase 3 and Phase 2 trial results for Sotyktu in psoriatic arthritis and systemic lupus erythematosus, and early promising data on its next-generation CD19-targeted CAR T cell therapy across multiple autoimmune diseases at prominent medical conferences. These clinical trial updates highlight Bristol-Myers Squibb's progress in expanding its immunology portfolio, strengthening its pipeline for potential future regulatory approvals and...

Description: Bristol-Myers Squibb Co (BMY) reports robust revenue growth and strategic milestones, raising full-year guidance amid competitive challenges.

Description: Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.

Description: Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 4.3% in the morning session after the company posted third-quarter financial results that beat expectations and raised its full-year sales forecast. Total revenues for the quarter came in at $12.22 billion, an increase of 2.8% from the same period a year ago, surpassing analyst estimates. The company also reported adjusted earnings of $1.63 per share, which was better than anticipated. Following these results, Bristol-Mye

Description: Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan

Description: Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called “lackluster” appeal and Bristol Myers’ prized schizophrenia drug again underwhelmed.

Description: Pfizer says ready to ‘pursue all legal avenues to enforce its rights’ against competing bid from Ozempic and Wegovy maker

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Estée Lauder (EL) beating profit estimates amid its brand turnaround plan, Mastercard (MA) topping third quarter expectations on its top and bottom lines, and Bristol-Myers Squibb (BMY) raising its revenue outlook. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.

Description: The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Description: Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year revenue guidance of $47.75 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $1.63 per share was 7.6% above analysts’ consensus estimates.

Description: The United States vitiligo market is projected to grow from $202.87 million in 2024 to $320.71 million by 2033, driven by a 5.22% CAGR from 2025. This growth is fueled by increasing awareness, innovative therapies, and improved diagnostic methods. Key treatment advancements include biologics, phototherapy, and topical solutions. Challenges include limited curative options and high treatment costs. States like California, New York, Texas, and Florida lead due to strong healthcare infrastructure.

Description: Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Description: Bristol Myers (BMY) delivered earnings and revenue surprises of +10.14% and +3.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Investing.com -- Bristol-Myers Squibb lifted its full-year outlook slightly after reporting third-quarter earnings and revenue that beat market expectations.

Description: Bristol Myers Squibb hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio. The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion. Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.

Description: Bristol Myers Squibb added nearly $1 billion to its bottom line in the third quarter as costs came down and revenue climbed on the strength of its newer drugs.

Description: PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported third-quarter earnings of $2.2 billion. On a per-share basis, the Princeton, New Jersey-based company said it had profit of $1.08. Earnings, adjusted for non-recurring costs, came to $1.63 per share.

Description: PRINCETON, N.J., October 30, 2025--Bristol Myers Squibb Reports Third Quarter Financial Results for 2025

Description: NORTHAMPTON, MA / ACCESS Newswire / October 29, 2025 / Bristol-Myers Squibb Company - Recently, the Innovative Cancer Medicines (ICM) initiative announced the enrollment of the first Nigerian patient in a pioneering demonstration project to provide ...

Description: Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know.

Description: There’s no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment. The dividend yield of the S&P 500 averages 1.2%, nearing its record low. Fortunately, there are several dividend stocks with a ... 5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade

Description: Following in the footsteps of David Solomon at Goldman Sachs and Jamie Dimon at JPMorgan, Ark Investments guru Cathie Wood recently warned of the potential for a reality check for the stock market after the massive Artificial Intelligence rally that has driven the major indices to all-time highs over the last three years. Of course, ... Uh Oh !! Cathie Wood Predicts “Reality Check” (Sell-off) – 5 High-Yield Dividend Safety Stocks

Description: Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product’ strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma’s recently announced €38 million Series C financing Saint-Genis-Pouil

Description: Bristol Myers Squibb (BMY) just reported new 52-week Phase 3 trial results for Sotyktu in adults with active psoriatic arthritis. The results show continuous clinical benefit, a steady safety profile, and evidence of joint damage limitation. See our latest analysis for Bristol-Myers Squibb. Bristol-Myers Squibb has been in the spotlight thanks to a steady stream of late-stage trial successes and high-profile partnerships, but the company’s share price reflects ongoing caution, with a 1-year...

Description: DelveInsight's Basal Cell Nevus Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, basal cell nevus syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Description: Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?

Description: As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.

Description: Bristol-Myers Squibb (BMY) said Monday that new data from a pivotal phase 3 trial showed that its ps

Description: Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.

Description: Besides Wall Street's top-and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

Description: PRINCETON, N.J., October 27, 2025--BMS Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

Description: Avidity Biosciences (RNA) has agreed to be acquired by Novartis (NVS) for $72 per share in a deal th

Description: Advances made in preclinical pipeline addressing neurodegenerative diseases Evotec receives US$ 25 m payment to support continued progression of joint programs HAMBURG, DE / ACCESS Newswire / October 27, 2025 / Evotec SE (Frankfurt Stock Exchange: ...

Description: PRINCETON, N.J., October 25, 2025--BMS Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR.

Description: Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength

Description: If you are weighing your next move with Bristol-Myers Squibb, you are definitely not alone. The stock has been on a rollercoaster, and plenty of investors are scratching their heads right now, asking whether the tough run offers a rare opportunity or signals deeper risks. Just in the past week, shares nudged up 1.8%, offering a glimmer of optimism. Yet, zoom out, and the scars of a challenging year are clear, with Bristol-Myers Squibb still down nearly 22% for 2024 and more than 30% over...

Description: We recently published Top 10 Trending Stocks Everyone’s Watching in Q4. Bristol-Myers Squibb Company (NYSE:BMY) is one of the trending stocks everyone’s watching. Morningstar’s Dave Sekera said in a recent program on Schwab Network that BMY is one of the top deep value stocks today. The analyst mentioned the stock’s dividend yield and valuation: “Well, […]

Description: Surging multibillion dollar acquisitions and a pipeline of innovative therapies define the current landscape. A strong focus on oncology theranostics, supported by new regulatory approvals, is rapidly advancing personalized cancer treatment possibilities.Chicago, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The global radiopharmaceuticals market was valued at US$ 6.8 billion in 2024 and is expected to reach US$ 13.4 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025–2033. The radiop

Description: Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through.

Description: Bristol Myers Squibb (BMY) closed at $44.54 in the latest trading session, marking a +2.18% move from the prior day.

Description: These five top dividend stock picks are waiting for growth and income investors to step up to the plate. Plus, they are rated Buy at top firms on Wall Street

Description: Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.

Description: Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.

Description: They are both yielding above 5%.

Description: The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Description: SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral presentation of the first disclosure of the safety and efficacy data from the global phase I US-Lung-101 study (NCT05983432) of iza-bren (BL-B01D1), a potentially first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Iza-bren is jointly developed by SystImmune and Br

Description: LegalMatch Highlight Critical Legal Considerations in Major Business Mergers and Acquisitions RENO, NEVADA / ACCESS Newswire / October 17, 2025 / Following the recent $1.5 billion acquisition of privately held Orbital Therapeutics by Bristol Myers ...

Description: New initiative aims to build capacity in high-prevalence areas to increase screening and prevention of hemoglobinopathies NORTHAMPTON, MA / ACCESS Newswire / October 17, 2025 /PATH has launched a groundbreaking initiative to address the rising burden ...